Geron (GERN)
(Real Time Quote from BATS)
$3.96 USD
-0.03 (-0.75%)
Updated Jun 5, 2024 03:06 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Geron Corporation [GERN]
Reports for Purchase
Showing records 181 - 200 ( 238 total )
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
2011 Results; Playing the Waiting Game for Year End Data
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
New Management - New Focus - New Execution - Imetelstat on Track for New Data
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
New Management - New Focus - New Execution - Imetelstat on Track for New Data
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
TO FOCUS ON ONCOLOGY - DISCONTINUES REGENERATIVE MEDICINE PROGRAM
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
TO FOCUS ON ONCOLOGY - DISCONTINUES REGENERATIVE MEDICINE PROGRAM
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
2Q11 UPDATE - DIVERSIFIED PIPELINE REDUCES RISK - 2012 PIVOTAL YEAR
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
2Q11 UPDATE - DIVERSIFIED PIPELINE REDUCES RISK - 2012 PIVOTAL YEAR
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
FIRST PATIENT IN SPINAL CORD TRIAL PASSES 180-DAY SAFETY MARK
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
FIRST PATIENT IN SPINAL CORD TRIAL PASSES 180-DAY SAFETY MARK
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Analyst Day Round 2 - Cell Therapy Programs Highlighted & Development Timelines Outlined
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Geron Corporation
Industry: Medical - Biomedical and Genetics
Analyst Day Round 2 - Cell Therapy Programs Highlighted & Development Timelines Outlined
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R